LY2811376 is a small molecule inhibitor of the protein kinase B-Raf, which plays a key role in the MAPK/ERK signaling pathway. It was developed by Eli Lilly and Company for the treatment of cancer and has undergone several preclinical and clinical trials.
Chemical name:
The chemical name for LY2811376 is 2-[4-(1H-pyrazol-4-yl)phenyl]-3-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]quinazolin-4(3H)-one.
Molecular formula:
The molecular formula of LY2811376 is C31H28F3N7O2.
Formula weight:
The formula weight of LY2811376 is 591.61 g/mol.
CAS No:
The CAS number of LY2811376 is 1194044-20-6.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
LY2811376 has been primarily developed for the treatment of cancer. It is a selective inhibitor of B-Raf, which plays an important role in the MAPK/ERK signaling pathway. This pathway is often dysregulated in cancer cells and contributes to their growth and survival. By inhibiting B-Raf, LY2811376 may help to slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of LY2811376 include:
Product mechanism:
LY2811376 works by inhibiting B-Raf, a protein kinase that plays a key role in the MAPK/ERK signaling pathway. This pathway is often dysregulated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting B-Raf, LY2811376 may help to restore normal cellular signaling and slow or stop the growth of cancer cells.
Safety:
LY2811376 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with LY2811376.
Side effects:
LY2811376 can cause several side effects in some patients. These can include:
Dosing information:
LY2811376 dosing varies depending on the clinical trial or indication. In some trials, LY2811376 was administered orally once daily, while in other trials it was administered twice daily. Doses ranged from 25 mg to 600 mg per day. The optimal dose of LY2811376 has not yet been established and further research is needed to determine the most effective dosing regimen.
Conclusion:
LY2811376 is a small molecule inhibitor of B-Raf that has shown potential as a treatment for cancer. By inhibiting B-Raf, LY2811376 may help to slow or stop the growth of cancer cells by restoring normal cellular signaling. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of LY2811376 in treating cancer
